Regulus UCSD Researchers Win Grant to Develop Extracellular RNA Biomarker Panel for Glioma Premium The funding coincides with publication of reports from the Extracellular RNA Consortium outlining growth and challenges in exosomal RNA-based diagnostics. Regulus Plans for New Clinical Trials, Third Drug Candidate in '15 Premium The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year. New Data Shows Higher Dose of Regulus HCV Drug Offers Better Viral Load Reductions Premium The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments. Regulus Hits Milestone in Biogen Idec microRNA Biomarker Deal Regulus said it was able to develop its miRNA extraction and profiling technology to meet the quality specifications set out by its partner. Alnylam Publishes Paper on Development of GalNAc Conjugate Delivery Technology Premium The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms. Nov 24, 2014 Data Point to Regulus Alport Drug Use in Late-stage Disease, Other Kidney Diseases Premium Nov 6, 2014 Regulus Weighs Dual Development Track for HCV Drug Premium Nov 6, 2014 Regulus Closes $103.5M Stock Offering Premium Nov 6, 2014 Wall Street in October Proves Tumultuous for Four RNAi/microRNA Shops Premium Oct 30, 2014 Regulus to Raise $90M in Stock Offering Premium Oct 23, 2014 Regulus Stock Surges on Positive Phase I HCV Data; Phase II on Deck for 2015 Premium Sep 25, 2014 Regulus Begins Natural History of Disease Study for Alport Syndrome Premium Aug 21, 2014 IP Update: Recent Patents Awarded to Alnylam, Baxter, GE Healthcare, and More Premium Aug 7, 2014 Regulus Sets Bar High for HCV Program, Sees Alport Drug in Phase II by 2015 Premium Aug 5, 2014 Regulus, Biogen Ink New Agreement for Potential MS miRNA Biomarkers Jul 24, 2014 Regulus Study Points to Possibility of Adverse Effects with Chronic miR-33 Inhibition Premium Jul 24, 2014 Regulus Receives Orphan Drug Designation for Alport Syndrome Drug Premium Jun 26, 2014 Microlin Lowers IPO Price Range as it Continues to Seek a Public Listing Premium Jun 26, 2014 People in the News: Paul Grint, Jennifer Doudna, Emmanuelle Charpentier Premium Jun 12, 2014 Regulus Weighs Spinoff of microRNA Biomarker Unit Premium May 15, 2014 Regulus Posts Increased Q1 Losses, Lower Revenues Premium Apr 10, 2014 Regulus Preclinical Data Shows Liver Cancer Biomarker Potential of microRNAs Premium Apr 9, 2014 At AACR, Researchers Highlight Multiple Roles of microRNAs in Cancer Mar 6, 2014 Regulus Provides Details on AstraZeneca Alliance, In-house Pipeline Programs Premium Feb 20, 2014 Regulus Names Alport Syndrome as Next Pipeline Indication Premium Load More Breaking News Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel Type 1 Diabetes GWAS, Fine-Mapping Leads to New Genetic Loci, Potential Drug Targets LSU Health Sciences Center Wins $2.4M to Lead SARS-CoV-2 Variant Sequencing Program NanoString Technologies, Parker Institute for Cancer Immunotherapy Partner on Cell Therapy Project BGI Americas Collaborating With Champions Oncology on Proteomic Cancer Research Personal Genome Diagnostics Inks Cancer Genomic Profiling Deal with Duke University Health System The Scan Missed Early Cases A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports. Limited Journal Editor Diversity A survey finds low diversity among scientific and medical journal editors, according to The Scientist. How Much of a Threat? Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned. PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.